Immutrin

Private

CambridgeHealthcare & Life Scienceshttps://www.immutrin.com/

Last Round

Series A

Mar 24, 2026

Total Funding Raised

$87M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Immutrin is a biotechnology company that develops antibody therapies designed to deplete systemic amyloid deposits and reverse amyloidosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

antibody therapyamyloidosis treatmentmonoclonal antibodytransthyretin amyloid cardiomyopathyATTR-CMamyloid removaltransthyretin amyloidosisATTRorgan damage reversalbiologic therapybiopharmadisease modifying therapymAbspreclinical biotechdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immutrin Comps

Public and private peers based on sector, stage, and business model.

Immutrin comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Immutrin Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Mar 24, 2026

View all Funding Rounds

Key People

Founding team and executive leadership

Mihriban Tuna

Chief Executive Officer

Executive Team

Simon Coulthard

Chief Financial Officer

Executive Team

Tolga Hassan

Chief Financial Officer

Executive Team

Immutrin Investors

Notable investors and investment history

Immutrin investors
Investor	Rounds
Cambridge Enterprise Ventures	Series A
Frazier Life Sciences	Series A
Cambridge Enterprise	Series A
Cambridge Innovation Capital	Series A
F-Prime Capital	Series A
Qiming Venture Partners	Series A
SR One	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 24, 2026
Raised $87M in Series A funding.

View all signals

Immutrin Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Immutrin Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Immutrin's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge

Employee Range14

Year Founded2019

Last FundingMar 24, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.